There were 1,885 press releases posted in the last 24 hours and 329,741 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image